eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
Basic research

MicroRNA-125b controls growth of ovarian granulosa cells in polycystic ovarian syndrome by modulating cyclin B1 expression

Jie Deng
Chanyu Li
Jianbo Luo
Jiaqiong Xie
Cong Peng
Xiaoyang Deng

Online publish date: 2019/06/14
Article file
- MicroRNA-125b.pdf  [1.08 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


MicroRNAs (miRNAs) are basically 23 nucleotide-long RNA molecules that control the expression of 30% of human genes by binding to the mRNAs and enforcing their post-transcriptional repression [1]. The miRNAs are involved in different cellular and physiological processes such as the cell cycle and apoptosis [2]. Accumulating evidence suggests that several microRNAs are aberrantly expressed in patients with diabetes mellitus, neurological disorders and malignancies. Therefore, miRs are considered to be prospective therapeutic targets for the management of these diseases [3]. It has been shown that miR-125b is aberrantly expressed in polycystic ovary syndrome (PCOS) [4]. However, its role in the pathogenesis of PCOS has yet not been investigated. Being one of the common types of endocrine disorders, PCOS affects approximately 4–10% of women at reproductive age [5, 6]. This syndrome generally refers to hyper-androgenism, insensitivity to insulin and oligoovulation [7]. Previous investigations performed over the last few decades have confirmed that PCOS is often linked with an increased risk of type 2 diabetes mellitus and the PCOS patients with mild hyperandrogenism but normal ovulation have the risk of developing this chronic disorder in future [8, 9]. Additionally, currently employed treatment strategies for PCOS include insulin sensitizers such as metformin, but these drugs can cause adverse effects that negatively affect the quality of life of patients [10–12]. This study aims to explore the role of miR-125b in PCOS and the therapeutic potential of miR-125b for the management of affected patients

Material and methods

Clinical samples and cell lines

The patients were recruited at the Department of Gynecology, The First Affiliated Hospital of Chengdu Medical College, China, from 2016 to 2018. The study was approved by the research ethics committee under approval number AHC/C270 of 2018 and informed consent was obtained a priori from all the women. All the women were in the same phase of the menstrual cycle and the mean age for normal and PCOS women was 34.5 and 34 respectively. We recruited 12 women with PCOS, undergoing laparoscopic investigation for infertility or ovarian drilling for ovulation induction. The diagnosis of PCOS was established according to the revised Rotterdam European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine criteria (2003) [13]. The PCOS subjects should present at least two of the following criteria: oligo- and/or anovulation, clinical hyperandrogenism and/or biochemical hyperandrogenism and polycystic ovaries after exclusion of other etiologies (e.g. congenital adrenal hyperplasia, androgen-secreting tumors, and Cushing’s syndrome). In the control group, we recruited 12 normally menstruating women who were undergoing laparoscopic sterilization, hysterectomy for benign conditions, and diagnostic laparoscopy for pelvic pain. The ovarian granulosa KGN cell line and the normal ovarian cell line SV40 were obtained from Cell Bank of Chinese Academy of Science (Shanghai, China) and maintained as described previously [14]. The KGN cell line has been used as an in vitro model for the study of PCOS as mentioned previously [14].

cDNA synthesis, qRT-PCR and transfections

Firstly the RNA of the cell lines and the tissue samples was extracted with the help of TRIzol reagent and then cDNA was generated from the isolated RNA using cDNA synthesis kit (Invitrogen). SYBR Green master mix was then used to quantify the relative expression of the miR-125b by the 2–Cq method. Lipofectamine 2000 reagent was employed to carry out the transfections of the miR-125b mimics (5´AGUGUUCAAUCCCAGAGUCCC 3´) and NC (5´ GUAGGAGUAGUGAAAGGCC 3´) following the manufacturer’s guidelines. The primers for miR-125b were forward 5-GCCCTCCCTGAGACCTCAA-3; and reverse 5-GTGCAGGGTCCGAGGT-3 and for cyclin B1 forward 5’-AAAGGCGTAACTCGAATGGA3´ and reverse 5’-CCGACCTTTTATTGAAGAGCA-3´.

Cell counting kit-8 (CCK-8) assay

After 48 h of transfection, KGN cells were grown in 96-well plates in three replicates at the density of 1.0 × 103 cells/well. The proliferation rate and the viability of the KGN cells were estimated by Cell Counting Kit-8 following the guidelines of the manufacturer. Around 10 µl of CCK-8 reagent was added into the wells at specific time intervals (12, 24, 48, 72 and 96 h) and the plates were then subjected to incubation for about 2 h at 37°C. Viability of the KGN cells was then measured by taking the absorbance at 450 nm.

Target identification

The miR-125b targets were identified with the help of TargetScan version 7.2 online software (http://www.targetscan.org).

Dual-luciferase reporter assay

The miR-125b mimics or NC were co-transfected with plasmid pGL3-cyclin B1´-UTR-WT or pGL3-cyclin B1´-UTR-MUT into KGN cells. Dual-luciferase reporter assay (Promega) was carried out at 48 h after transfection. Renilla luciferase was used for normalization.

DAPI staining for apoptosis

For DAPI staining, the transfected ovarian granulosa KGN cells (0.6 × 106) were grown in 6-well plates. After an incubation period of around 12 h, the KGN cells were subjected to incubation for 24 h at 37°C. As the cells sloughed off, 25 µl cell cultures were put onto glass slides and subjected to staining with DAPI. The slides were covered with a cover slip and examined with a fluorescent microscope.

Cell cycle analysis

After transfection the KGN cells were subjected to culturing for 24 h at 37°C. The KGN cells were harvested and the PBS washed. Afterwards, the KGN cells were stained with propidium iodide (PI) and the distribution of the cells in cell cycle phases was assessed by a FACS flow cytometer.

.Western blotting

KGN cells were firstly subjected to washing with ice-cold PBS and then suspended in a lysis buffer at 4°C and then shifted to 95°C. Thereafter, the protein content of each cell extract was determined by Bradford assay. About 40 µg of protein was loaded from all samples and separated by SDS-PAGE before being shifted to polyvinylidene fluoride membrane. The membranes were then subjected to treatment with TBS and then exposed to primary antibodies at 4°C. Thereafter, the cells were administered with appropriate secondary antibodies and the proteins of interest were visualized by enhanced chemiluminescence reagent.

Statistical analysis

Data are presented as mean ± SD. Statistical analysis was done using Student’s t-test with GraphPad prism 7 software. Values of p < 0.05 were taken as indicative of a significant difference.


miR-125b is upregulated in PCOS ovaries and KGN ovarian granulosa cells

The transcript profile of miR-125b was examined in normal and polycystic ovary specimens by qRT-PCR (Figure 1 A). The results showed that miR-125b exhibited aberrant expression and was significantly upregulated (p < 0.05) in all polycystic ovary tissues (Figure 1 B). The expression of miR‑125b was almost twice as high in the ovarian tissues of PCOS patients when compared to the ovarian tissues of healthy women. The miR-125b levels were also examined in KGN PCOS cells and normal SV40 ovarian cells. It was found that miR-125b expression was around 5.6-fold higher in the KGN cells in comparison to the normal SV40 cells (Figure 1 B).

Inhibition of miR-125b KGN cells triggers G2/M arrest

Next, we sought to decipher the role of miR-125b in PCOS and for that the KGN cells were subjected to transfection with either the miR-125b inhibitor or NC. The suppression of miR-125b in KGN cells was confirmed by qRT-PCR, which showed that transfection of the KGN cells with miR-125b inhibition caused around 10-fold reduction in miR-125b expression relative to NC transfected cells (Figure 2 A). Next the proliferation rate of the NC and miR-125b inhibitor transfected KGN cells was estimated by CCK-8 assay and it was revealed that the transfection of miR-125b inhibitor in the KGN cells caused a significant decline in their proliferation rate (Figure 2 B). Next, distribution of NC and miR-125b inhibitor KGN cells was estimated by flow cytometry to reveal the underlying reason for reduction in the proliferation of miR-143 mimic transfected cells. The flow cytometry analysis showed that miR-125b inhibitor transfection (i.e., miR-125b suppression) caused G2/M arrest of the KGN cells (Figure 2 C). The percentage of the G2/M KGN cells increased from 13.5% in the control to 55.1% in the miR-125b inhibitor transfected KGN cells. Next DAPI staining was also performed to determine whether miR-125b inhibition triggers apoptosis in the KGN cells. DAPI staining together with caspase 3 expression analysis revealed that miR-125B did not induce apoptotic cell death in the KGN cells transfected with NC or miR-125b inhibitor (Figures 2 D and E).

miR-125b targets cyclin B1 in gastric cancer cells

The target of miR-125b in KGN ovarian granulosa cells was determined by online TargetScan analysis. Cyclin B1 was identified as the potential target of miR-125b in KGN cells (Figure 3 A), which was further confirmed by the luciferase assay (Figure 3 B) and therefore the expression levels of cyclin B1 were investigated in NC as well as the miR-125b inhibitor transfected KGN ovarian granulosa cells. The results indicated that expression of cyclin B1 was considerably upregulated as depicted by the western blot analysis (Figure 3 C). Next, we sought to reveal the impact of the cyclin B1 silencing on the viability of KGN cells. Therefore, the KGN cells were transfected with NC or Si-cyclin B1 and cyclin-B1 silencing was confirmed by qRT-PCR analysis, which showed 5.7-fold depletion of the cyclin B1 expression in Si-cyclin B1 transfected cells relative to the NC transfected KGN cells (Figure 3 D). The silencing of the cyclin B1 was also confirmed by western blot analysis (Figure 3 E). Further, the results of the CCK-8 showed that Si-cyclin B1 transfection (i.e., cyclin B1 silencing) caused significant reduction in KGN cell viability (Figure 3 F). Cell cycle analysis of the NC or Si-cyclin B1 cells showed that miR-125b inhibition triggers G2/M arrest (Figure 4 A). The percentage of the G2/M phase KGN cells increased from 20.4% in NC transfected KGN cell to 61% in Si-cyclin B1 transfected cells. However, miR-125b silencing in the KGN cells did not trigger apoptotic cell death as indicated by DAPI and caspase-3 expression (Figures 4 B and C).

Cyclin B1 is essential for miR-125b mediated effects on KGN cell proliferation

Since miR-125b inhibition and cyclin B1 silencing both inhibited the growth of the KGN cells, we sought to find out if miR-125b overexpression could nullify the impact of cyclin B1 silencing in KGN cells. Interestingly, it was observed that miR-125b overexpression in the Si-cyclin B1 transfected KGN had no impact on the cyclin B silencing induced effects on the KGN proliferation (Figure 5 A). Nonetheless, overexpression of cyclin B1 in the miR-125b inhibitor transfected KGN cells rescued the effects of miR-125b inhibition on the viability, indicating that cyclin B1 is imperative for miR-125b mediated effects on the KGN proliferation (Figure 5 B).


The PCOS is one of the most commonly diagnosed metabolic and endocrine abnormalities [5]. Although PCOS affects up to 10% of the women at reproductive age, the underlying reason for its pathogenesis has not been clarified yet. The pathogenesis of PCOS has been characterized by the alteration of gonadotropin production, upsurge of steroidogenic enzymes, and insensitivity to insulin and oligoovulation, which impairs fertility [6]. Currently insulin sensitizers such as metformin are used for the treatment of PCOS, but these drugs are associated with adverse effects. Therefore, there is a need to develop more efficient and safer treatment strategies for the management of PCOS. Over the years, miRs have been described as potential therapeutic targets for the management of diseases [3]. The possible modes of action for miRNA within the pathophysiology of PCOS have only been sparsely investigated, and thus there are only a few studies that investigate the relationship between miRNA and PCOS. It is believed that miRs may act as potential targets for the pharmacological agents in PCOS patients. For example, it has been shown that miR-93 controls the proliferation of KGN cells [13] and there is overexpression of miR-125b [4] in polycystic ovaries. Moreover, it has been shown that miR-93 is overexpressed and this overexpression inhibits GLUT4 expression in adipose tissues of PCOS patients [15]. The findings of the present study indicate that miR-125b is considerably upregulated in the polycystic ovaries as well the ovarian granulosa KGN cell lines. When the expression of miR-125b is suppressed, the proliferation of KGN cells is inhibited by inducing G2/M cell cycle arrest. These results comply with previous investigations where miRs have been reported to be aberrantly expressed in polycystic ovaries. For instance, miR-21, miR-27b, miR-103 and miR-155 tend to show enhanced expression in PCOS patients [16]. Another study reported that miR-21 and 146a expression was enhanced in PCOS patients and this overexpression was associated with DNA damage in a mouse model of PCOS [17].
Additionally, it was demonstrated that miR-125b exerts its inhibitory effects by modulating cyclin B1 expression. Cyclin B1 silencing resulted in similar effects on the viability of KGN cells as that of miR-125b silencing. Cyclin B1 has been found to control the transition of the cells from G2 phase to M phase during the cell cycle [18]. This further supports our results that miR-125b suppresses the proliferation of granulosa cells by targeting cyclin B1 and cyclin B1 overexpression could overcome the effects of miR-125b suppression on the proliferation of KGN cells.
In conclusion, it can be concluded that miR-125b regulates the viability of the ovarian granulosa cells in PCOS patients, and thus miR-125 might be addressed as a potential therapeutic target for the management of PCOS. Further research should be performed to clarify the role of miR-125 in PCOS pathogenesis.

Conflict of interest

The authors declare no conflict of interest.


1. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2015; 122: 6-7.
2. Yang M, Zhang L, Wang X, Zhou Y, Wu S. Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma promotes cell proliferation. Arch Med Sci 2018; 14: 1333-9.
3. Slaby O, Svoboda M, Fabian P, et al Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-402.
4. Sen A, Prizant H, Light A, et al. Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc Natl Acad Sci 2014; 111: 3008-13.
5. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nature Rev Dis Primers 2016; 2: 16057.
6. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the McCartney CR, Marshall JC. Polycystic ovary syndrome. New Engl J Med 2016; 375: 54-64.
7. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2014; 6: 1-13.
8. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-6.
9. Naderpoor N, Shorakae S, de Courten B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human Reprod Update 2015; 21: 560-74.
10. Lo JC, Yang J, Gunderson EP, et al. Risk of type 2 diabetes mellitus following gestational diabetes pregnancy in women with polycystic ovary syndrome. J Diabetes Res 2017; 2017: 5250162.
11. Escobar-Morreale HF, Roldán-Martín MB. Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis. Diabetes Care 2016; 39: 639-48.
12. Murri M, Insenser M, Fernández-Durán E, et al. Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. Metabolism 2018; 86: 49-60.
13. Jiang L, Huang J, Li L, et al. MicroRNA-93 promotes ovarian granulosa cells proliferation through targeting CDKN1A in polycystic ovarian syndrome. J Clin Endocrinol Metabol 2015; 100: E729-38.
14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
15. Chen YH, Heneidi S, Lee JM, et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes 2013; 62: 2278-86.
16. Sørensen A, Wissing M, Salö S, et al. MicroRNAs related to polycystic ovary syndrome (PCOS). Genes 2014; 5: 684-708.
17. Salimi-Asl M, Mozdarani H, Kadivar M. Up-regulation of miR-21 and 146a expression and increased DNA damage frequency in a mouse model of polycystic ovary syndrome (PCOS). BioImpacts 2016; 6: 85-91.
18. Yuan J, Krämer A, Matthess Y, et al. Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene 2006; 25: 1753-62.
Copyright: © 2019 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe